229 related articles for article (PubMed ID: 36263866)
1. A literature perspective on the pharmacological applications of yohimbine.
Jabir NR; Firoz CK; Zughaibi TA; Alsaadi MA; Abuzenadah AM; Al-Asmari AI; Alsaieedi A; Ahmed BA; Ramu AK; Tabrez S
Ann Med; 2022 Dec; 54(1):2861-2875. PubMed ID: 36263866
[No Abstract] [Full Text] [Related]
2. Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
Millan MJ; Newman-Tancredi A; Audinot V; Cussac D; Lejeune F; Nicolas JP; Cogé F; Galizzi JP; Boutin JA; Rivet JM; Dekeyne A; Gobert A
Synapse; 2000 Feb; 35(2):79-95. PubMed ID: 10611634
[TBL] [Abstract][Full Text] [Related]
3. Selectivity of atipamezole, yohimbine and tolazoline for alpha-2 adrenergic receptor subtypes: implications for clinical reversal of alpha-2 adrenergic receptor mediated sedation in sheep.
Schwartz DD; Clark TP
J Vet Pharmacol Ther; 1998 Oct; 21(5):342-7. PubMed ID: 9811433
[TBL] [Abstract][Full Text] [Related]
4. Effects of alpha-adrenoreceptor antagonists on apoptosis and proliferation of pancreatic cancer cells in vitro.
Shen SG; Zhang D; Hu HT; Li JH; Wang Z; Ma QY
World J Gastroenterol; 2008 Apr; 14(15):2358-63. PubMed ID: 18416462
[TBL] [Abstract][Full Text] [Related]
5. Yohimbine disrupts prepulse inhibition in rats via action at 5-HT1A receptors, not alpha2-adrenoceptors.
Powell SB; Palomo J; Carasso BS; Bakshi VP; Geyer MA
Psychopharmacology (Berl); 2005 Jul; 180(3):491-500. PubMed ID: 15719216
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the receptor involved in the central hypotensive effect of rilmenidine and moxonidine.
Bock C; Niederhoffer N; Szabo B
Naunyn Schmiedebergs Arch Pharmacol; 1999 Apr; 359(4):262-71. PubMed ID: 10344524
[TBL] [Abstract][Full Text] [Related]
7. Alpha2 antagonist yohimbine suppresses maintained firing of rat prefrontal neurons in vivo.
Kovács P; Hernádi I
Neuroreport; 2003 May; 14(6):833-6. PubMed ID: 12858042
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders--the case of yohimbine.
Holmes A; Quirk GJ
Trends Pharmacol Sci; 2010 Jan; 31(1):2-7. PubMed ID: 20036429
[TBL] [Abstract][Full Text] [Related]
9. Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors.
Newman-Tancredi A; Nicolas JP; Audinot V; Gavaudan S; Verrièle L; Touzard M; Chaput C; Richard N; Millan MJ
Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug; 358(2):197-206. PubMed ID: 9750005
[TBL] [Abstract][Full Text] [Related]
10. Multiple receptors involved in peripheral alpha 2, mu, and A1 antinociception, tolerance, and withdrawal.
Aley KO; Levine JD
J Neurosci; 1997 Jan; 17(2):735-44. PubMed ID: 8987795
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular reactivity to mental stress is not affected by alpha2-adrenoreceptor activation or inhibition.
Philippsen C; Hahn M; Schwabe L; Richter S; Drewe J; Schachinger H
Psychopharmacology (Berl); 2007 Feb; 190(2):181-8. PubMed ID: 17111173
[TBL] [Abstract][Full Text] [Related]
12. Human sympathetic activation by alpha2-adrenergic blockade with yohimbine: Bimodal, epistatic influence of cytochrome P450-mediated drug metabolism.
Le Corre P; Parmer RJ; Kailasam MT; Kennedy BP; Skaar TP; Ho H; Leverge R; Smith DW; Ziegler MG; Insel PA; Schork NJ; Flockhart DA; O'connor DT
Clin Pharmacol Ther; 2004 Aug; 76(2):139-53. PubMed ID: 15289791
[TBL] [Abstract][Full Text] [Related]
13. Yohimbine impairs extinction of cocaine-conditioned place preference in an alpha2-adrenergic receptor independent process.
Davis AR; Shields AD; Brigman JL; Norcross M; McElligott ZA; Holmes A; Winder DG
Learn Mem; 2008 Sep; 15(9):667-76. PubMed ID: 18772254
[TBL] [Abstract][Full Text] [Related]
14. Anticancer potential of yohimbine in drug-resistant oral cancer KB-ChR-8-5 cells.
Jabir NR; Khan MS; Alafaleq NO; Naz H; Ahmed BA
Mol Biol Rep; 2022 Oct; 49(10):9565-9573. PubMed ID: 35970968
[TBL] [Abstract][Full Text] [Related]
15. [Yohimbine in therapy of erectile dysfunction].
Pittler MH
Fortschr Med; 1998 Jan; 116(1-2):32-3. PubMed ID: 9522535
[TBL] [Abstract][Full Text] [Related]
16. Yohimbine in erectile dysfunction: the facts.
Morales A
Int J Impot Res; 2000 Mar; 12 Suppl 1():S70-74. PubMed ID: 10845767
[TBL] [Abstract][Full Text] [Related]
17. Reduction in ultraviolet B light-induced erythema by oxymetazoline and brimonidine is mediated by different α-adrenoceptors.
Hsia E; Tian M; Gil D
Exp Dermatol; 2018 Jul; 27(7):763-768. PubMed ID: 29637626
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of clonidine and yohimbine on pupillary diameter at different illumination levels.
Phillips MA; Szabadi E; Bradshaw CM
Br J Clin Pharmacol; 2000 Jul; 50(1):65-8. PubMed ID: 10886121
[TBL] [Abstract][Full Text] [Related]
19. Yohimbine in erectile dysfunction: would an orphan drug ever be properly assessed?
Morales A
World J Urol; 2001 Aug; 19(4):251-5. PubMed ID: 11550783
[TBL] [Abstract][Full Text] [Related]
20. Structure-Based Drug Design of ADRA2A Antagonists Derived from Yohimbine.
Chayka A; Česnek M; Kužmová E; Kozák J; Tloušt'ová E; Dvořáková A; Strmeň T; Brož B; Osifová Z; Dračínský M; Mertlíková-Kaiserová H; Janeba Z
J Med Chem; 2024 Jun; 67(12):10135-10151. PubMed ID: 38857067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
